Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Nicholas Lydon currently holds 4,570 shares of Blueprint Medicines Corp (BPMC), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Nicholas Lydon has been a net seller of BPMC stock. They have purchased $0 and sold $16.7M worth of shares.
Nicholas Lydon's most recent insider trade was on Jun 12, 2024, when they sold 4,570 shares at $0.00 per share.
Nicholas Lydon serves as Executive at Blueprint Medicines Corp (BPMC). They have executed 40 insider transactions totaling $16.7M over their tenure at the company.
Nicholas Lydon holds the position of Executive at Blueprint Medicines Corp, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 10 years and currently hold a stake valued at $0.
Nicholas Lydon has shown a selling trading pattern, with $0 in total purchases and $16.7M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Nicholas Lydon was on Mar 14, 2017, when they sold $2.7M worth of BPMC shares. This transaction involved 68,600 shares at $40.06 per share.
Nicholas Lydon currently owns 4,570 shares of Blueprint Medicines Corp (BPMC), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Nicholas Lydon's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Nicholas Lydon has 40 Form 4 filings on record as an insider at Blueprint Medicines Corp.
Set alerts for Nicholas Lydon and 40,000+ other insiders.